Tumor Cell Or Cancer Cell Patents (Class 435/7.23)
  • Patent number: 10732184
    Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against protease-activated receptor 1 (PAR1) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without ovarian cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for ovarian cancer in the subject. Furthermore the invention relates to differential diagnosis of cancer and the prediction of the response of a subject to be treated for cancer with a drug.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: August 4, 2020
    Assignee: CellTrend GmbH
    Inventors: Harald Heidecke, Kai Schulze-Forster
  • Patent number: 10733784
    Abstract: Some embodiments include an apparatus for processing radio frequency multiplexed cell images such as single-cell images, for example radio frequency multiplexed excitation (FIRE) images. The images can be from a particle analyzer, such as a flow and scanning cytometer or a laser scanning microscope. Some embodiments include an apparatus for displaying radio frequency multiplexed cell images such as FIRE images.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: August 4, 2020
    Assignee: BECTON, DICKINSON AND COMPANY
    Inventor: Christopher J. Wolf
  • Patent number: 10723804
    Abstract: The invention relates to an isolated antigenic polypeptide comprising an epitope for binding an MCM2 monoclonal antibody, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of: (a) the amino acid as shown in FIG. 1; and (b) the amino acid sequence wherein said sequence is a variant polypeptide modified by addition, deletion or substitution of at least one amino acid residue as represented in FIG. 1.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: July 28, 2020
    Inventor: Sushant Dhanvijay
  • Patent number: 10718777
    Abstract: The present invention relates to methods of visualizing targets in histological samples, e.g. biopsy samples, wherein the methods comprise staining of the sample with (i) one or more target specific immunochemical stains, and (ii) a histological stain for specific tissue components e.g. iron, mucins glycogen, amyloid, nucleic acids, etc., e.g. hematoxilyn and/or eosin stains or the like, that is used to enhance contrast in the microscopic image of a tissue sample, highlight morphologic structures in the sample for viewing, define and examine tissues, cell populations, or organelles within individual cells. Methods may further comprise evaluation of expression of one or more targets in the sample. The disclosed methods are useful for medical diagnostics.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: July 21, 2020
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventor: Jesper Lohse
  • Patent number: 10711068
    Abstract: Anti-CD133 monoclonal antibodies having advantageous properties; products, compositions and kits comprising the monoclonal antibodies; methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: July 14, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Thomas D. Pfister, Robert J. Kinders, Tony Navas
  • Patent number: 10697972
    Abstract: A method of detecting tumor cells in a sample containing cells. In the method, a sample is encapsulated to produce a capsule with the sample encapsulated therein. The capsule containing the sample encapsulated therein is incubated under cell culture conditions suitable for supporting cell activity and growth of tumor cells and the encapsulated sample from the incubated capsule is contacted with a conditionally active antibody that has a higher binding affinity to a cell surface protein of a tumor cell under a first value of a condition of a tumor microenvironment, in comparison with the binding affinity of the conditionally active antibody to the same cell surface protein under a second value of the condition.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: June 30, 2020
    Assignee: BioAtla, LLC
    Inventor: Jay M. Short
  • Patent number: 10690611
    Abstract: A sensor device (30) includes an oscillation unit formed in a semiconductor integrated circuit (40) and having an oscillation frequency which changes in accordance with a physical property of an analyte which comes into contact with the oscillation unit; an oscillation frequency detection unit configured to detect the oscillation frequency, and one or more electrode pairs (36) configured to move a specific analyte dispersed in liquid to an arbitrary location.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 23, 2020
    Assignee: SHARP KABUSHIKI KAISHA
    Inventors: Akira Saito, Daiki Sato, Takeshi Mitsunaka, Kunihiko Iizuka
  • Patent number: 10685737
    Abstract: Combination therapies are automatically discovered that provide statistically significantly greater protection against a specific outcome, compared to therapies with fewer treatments. A dataset is received that associates each of a plurality of respective individual treatments with a corresponding outcome and a corresponding set of confounding factors. A plurality of new potential combination therapies are combined iteratively. The received dataset is used to automatically identify at least one candidate combination therapy of the new potential combination therapies that provides a statistically significantly greater protection against an outcome with reference to each of the plurality of respective individual treatments.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: June 16, 2020
    Assignee: International Business Machines Corporation
    Inventors: Gang Hu, Xiang Li, Haifeng Liu, Guo Tong Xie, Ping Zhang
  • Patent number: 10677801
    Abstract: The present invention relates to compositions and methods for-determining a treatment course of action. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies and administration of appropriate treatments.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: June 9, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventor: Daniel Hayes
  • Patent number: 10668093
    Abstract: The present invention relates to a method for treating a cancer with the combination of a topoisomerase II inhibitor (TOP2 inhibitor) and a histone deacetylation inhibitor (HDACi), provides synergistic cancer cell-killing effects, and prolonged overall survival, especially when the expression of checkpoint kinase 1 (CHK-1) is low.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: June 2, 2020
    Assignee: National Yang-Ming University
    Inventor: Jin-Hwang Liu
  • Patent number: 10656058
    Abstract: The present invention relates to a material for aggregating blood cells, used in the preparation of a paraffin block for diagnosing circulating tumor cells (CTCs), and a method for preparing a paraffin block using the same, and more specifically, to a method for detecting CTCs present in the blood through blood sample collection in the preparation of a paraffin block from CTCs, which are present in a very small amount in the blood. The present invention is non-invasive and simple, and thus is very useful for the diagnosis of cancer recurrence and metastatic cancer and for prognosis prediction, and can be a remarkable breakthrough in cancer treatment through the analysis of the onset, metastasis and recurrence mechanisms of cancer.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: May 19, 2020
    Assignee: NATIONAL CANCER CENTER
    Inventors: Hee Jin Chang, Sun Young Kim, Ji Yeon Baek, Hyun Yang Yeo
  • Patent number: 10656073
    Abstract: Methods of optically marking and sorting adherent cells are provided. The methods include providing a plurality of adherent cells attached to a substrate, each adherent cell of the plurality of adherent cells having an optical marker. The methods also include selectively applying light energy to a subset of the plurality of adherent cells, and detaching the plurality of adherent cells from the substrate. These methods also provide the sorting of the plurality of adherent cells.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: May 19, 2020
    Assignee: University of Washington
    Inventors: Daniel T. Chiu, Chun-Ting Kuo, Jiangbo Yu
  • Patent number: 10641767
    Abstract: The invention relates to compositions and methods for the immunoassay of an analyte of interest. The analyte is detected in an immunoassay using three or more antibodies, where in each antibody specifically binds to a different epitope on the analyte. When the analyte of interest in a clinical marker for an acute disease, the detection of the analyte by immunoassay is a diagnosis of the occurrence of the disease.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: May 5, 2020
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Pamela Anne Frank, Meghan Elizabeth Hawkes, Shannon Reishma Lobin, Cary James Miller, Zhen Yang
  • Patent number: 10610125
    Abstract: Methods of treating and evaluating subjects having neoactive mutants are described herein.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: April 7, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Lenny Dang, Valeria Fantin, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Francesco G. Salituro, Jeffrey O. Saunders, Shin-San Michael Su, Katharine Yen
  • Patent number: 10613090
    Abstract: The present disclosure is directed toward methods and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of the identified markers, as compared to a control. The expression of the markers in Table 2A is increased in samples from subjects with cancer as compared to the expression level in subjects without cancer and the expression of the markers in Table 2B are decreased in samples from subjects with cancer as compared to the expression level in subjects without cancer. The sample may be lacrimal secretions or eye wash fluid, saliva, or other biological fluids. The kits may include an eye wash kit, collection tubes and protease inhibitors, or protein stabilizers.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: April 7, 2020
    Assignee: Ascendant Diagnostics, LLC
    Inventors: Anna Daily, Lindsay Rutherford
  • Patent number: 10577439
    Abstract: Some embodiments described herein relate to new polymer coatings for surface functionalization and new processes for grafting pre-grafted DNA-copolymers to surface(s) of substrates for use in DNA sequencing and other diagnostic applications.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: March 3, 2020
    Assignee: Illumina Cambridge Limited
    Inventors: Andrew A. Brown, Wayne N. George, Alexandre Richez, Anne-Cecile Dingwall, Xavier von Hatten
  • Patent number: 10576102
    Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: March 3, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yamashita, Tomohisa Watanabe, Tetsuro Hikichi
  • Patent number: 10564167
    Abstract: The present invention relates to methods for detecting the chromatin state of a cell based on recording a super resolution image of nucleosome organization and correlating said imaged with size of nucleosomal clutches, nucleosomal density and/or number of nucleosomes per nucleosomal clutches. Additionally, the invention relates to a kit comprising a first antibody capable of specifically binding to a histone protein and a photoswitchable fluorophore linked-secondary antibody and the use of the kit of the invention for detecting the chromatin state of a cell and isolating a cell in an open chromatin state or in a closed chromatin state. The invention also relates to a device adapted to detect the chromatin state of a cell.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: February 18, 2020
    Assignees: FUNDACIÓ INSTITUT DE CIÈNCIES FOTÓNEQUES, FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA, INSTITUCIÓ CATALANA DE RECERCA↑ESTUDIS AVANçATS
    Inventors: Melike Lakadamyali, Carlo Manzo, Maria Aurelia Ricci, Maria Pia Cosma
  • Patent number: 10537641
    Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: January 21, 2020
    Assignee: The USA as represented by the Secretary, Department of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Patent number: 10527624
    Abstract: The present invention describes a method for detecting castration-resistant prostate cancer (CRPC) in a patient afflicted with prostate cancer comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to detect circulating tumor cells (CTC), (b) determining prevalence of a CTC subpopulation associated with CRPC comprising detecting a measurable feature of each biomarker in a panel of morphological and protein biomarkers, and (c) comparing the prevalence of said CTC subpopulation to a predetermined threshold value, wherein the prevalence of the CTC subpopulation associated with CRPC above said predetermined threshold value is indicative of CRPC. In some embodiments, the CTC subpopulation associated with CRPC comprises CK? CTCs. In some embodiments, the CTC subpopulation associated with CRPC comprises small CTCs.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: January 7, 2020
    Assignee: Epic Sciences, Inc.
    Inventor: Ryan Dittamore
  • Patent number: 10501523
    Abstract: The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: December 10, 2019
    Assignee: SANOFI
    Inventors: Marielle Chiron-Blondel, Diether Lambrechts, Emmanuelle Magherini, Vincent Thuillier
  • Patent number: 10494424
    Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: December 3, 2019
    Assignee: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Sunil Thomas, James Mullin, George C. Prendergast
  • Patent number: 10485849
    Abstract: Peptides from syndecan 1 and methods of use therefor are described. These peptides can inhibit very late antigen-4 (VLA-4) interaction with vascular endothelial growth factor-2 (VEGFR2), thereby preventing tumor cell growth and tissue invasion.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 26, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Alan Rapraeger, Oisun Jung
  • Patent number: 10487152
    Abstract: The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: November 26, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Joseph A Mollick, Pearline Teo, Paul J Utz
  • Patent number: 10479827
    Abstract: Disclosed is a monoclonal antibody reacting with a glycopeptide, wherein the glycopeptide contains a core fucose moiety and at least 4 contiguous amino acid residues that are located on the C-terminal side of a glycosylated asparagine moiety, and both of the core fucose moiety in the glycopeptide and an amino acid residue that is located apart by at least three amino acid residues from the C-terminal of the glycosylated asparagine moiety in the glycopeptide are epitopes for the antibody.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: November 19, 2019
    Assignee: SYSMEX CORPORATION
    Inventors: Yukiko Kataoka, Tsuyoshi Nomura, Koji Fukagawa, Yuriko Egashira, Yukiko Higa
  • Patent number: 10473660
    Abstract: The invention pertains to diagnosis and treatment of ovarian cancer (OC), cervical cancer (CC), or colorectal cancer (CRC). One embodiment of the invention provides a method of identifying OC, CC, or CRC based on the level of RHAMM in the urine of a subject. Another embodiment of the invention provides a method of identifying OC based on the level of RHAMM in the urine and CA125 in the blood of a subject. The invention also pertains to monitoring the efficacy of a treatment of OC, CC, or CRC based on the level of RHAMM protein in the urine and/or the level of CA125 in the blood. Another embodiment of the invention provides devices and reagents to assay RHAMM in a urine sample and optionally, assay CA125 in a blood sample.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: November 12, 2019
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Patricia Ann Kruk, Stephanie Tania Buttermore
  • Patent number: 10435472
    Abstract: The instant invention provides for a new method of treating bone metastasis diseases in subjects, wherein said method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment, wherein said treatment comprises the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on said specific protein levels in one or more body fluids of the subject.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: October 8, 2019
    Assignee: Merck Patent GmbH
    Inventors: Josef Straub, Eike Staub
  • Patent number: 10429294
    Abstract: Methods of optically marking and sorting adherent cells are provided. The methods include providing a plurality of adherent cells attached to a substrate, each adherent cell of the plurality of adherent cells having an optical marker. The methods also include selectively applying light energy to a subset of the plurality of adherent cells, and detaching the plurality of adherent cells from the substrate. These methods also provide the sorting of the plurality of adherent cells.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: October 1, 2019
    Assignee: University of Washington
    Inventors: Daniel T. Chiu, Chun-Ting Kuo, Jiangbo Yu
  • Patent number: 10426849
    Abstract: The invention is directed to a staining composition and to the use of the staining composition in staining ocular tissue. In a first aspect, the invention provides a staining composition comprising a vital dye and a density increasing compound chosen from the group consisting of water soluble polymers and small inert molecules.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: October 1, 2019
    Assignee: D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.
    Inventor: Gerrit Reinold Jacob Melles
  • Patent number: 10400045
    Abstract: In various embodiments various cancer specific antibodies and immunoconjugates are provided. In certain embodiments the antibodies specifically bind and are internalized into a prostate cancer cell, where the antibodies specifically binds cells that express or overexpress a CD46, and where the antibodies specifically bind sushi domain 1 of said CD46 (CD46 CPP1).
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: September 3, 2019
    Assignee: The Regents of the University of California
    Inventor: Bin Liu
  • Patent number: 10388409
    Abstract: Healthcare object (HCO) discriminator systems and methods are presented. Systems can obtain a digital representation of a scene via a sensor interface. An HCO discriminator platform analyzes the digital representation to discriminate objects within the scene as being associated with a type of HCO or as being unrelated to a type of HCO. Once the HCO recognition platform determines that a type of HCO is relevant, it instantiates an actual HCO. The HCO can be routed to one or more destinations based on routing rules generated from a template or based on the manner in which the objects in the scene were discriminated.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: August 20, 2019
    Assignee: Nant Holdings IP, LLC
    Inventors: Patrick Soon-Shiong, John Zachary Sanborn, Stephen Charles Benz, Charles Joseph Vaske
  • Patent number: 10389909
    Abstract: An image processing apparatus performs: acquiring target image data representing a target image and including a plurality of pixel values each having a plurality of component values; generating first image data including a plurality of first pixel values each being related to a minimum value among the plurality of component values of corresponding one of the plurality of pixel values; specifying a plurality of first edge pixels using the first image data; generating second image data including a plurality of second pixel values each being related to a maximum value among the plurality of component values of corresponding one of the plurality of pixel values; specifying a plurality of second edge pixels using the second image data; and specifying a plurality of edge pixels using the plurality of first edge pixels and the plurality of second edge pixels, the plurality of edge pixels constituting an edge in the target image.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: August 20, 2019
    Assignee: Brother Kogyo Kabushiki Kaisha
    Inventor: Ryuji Yamada
  • Patent number: 10344315
    Abstract: A method of retrieving fetal cells from an endocervical sample by removing the mucus from the endocervical sample by disassociating fetal cells and maternal cells in the endocervical sample; and isolating disassociated fetal cells from other cells in the endocervical sample. Also provided is a method of retrieving fetal cells from an endocervical sample, by obtaining a mixture of disassociated cells prepared by the above method, treating the cells with a fetal-specific antibody, identifying cells that have bound to the fetal-specific antibody, and isolating the identified cells. The disassociated cell prepared by the above method can be analyzed and used for a variety of purposes including, but not limited to, the identification of fetal cells among cervical cells, determination of fetal cell density to predict high risk pregnancy, genetic analysis of fetal cells, and determination of growth factor or other biomarker expression to predict obstetrical disorders.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: July 9, 2019
    Assignee: Wayne State University
    Inventors: D. Randall Armant, Michael P. Diamond
  • Patent number: 10316092
    Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H5 ligand of the B7-H5:CD28H pathway, and to the uses of such molecules in the treatment and diagnosis of autoimmune disease, transplant rejection and other inflammatory diseases.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: June 11, 2019
    Assignees: THE JOHN HOPKINS UNIVERSITY, MEDIMMUNE, LLC
    Inventors: Sheng Yao, Lieping Chen, Linda Liu, Solomon Langermann
  • Patent number: 10311571
    Abstract: The present invention relates to an image analysis method for providing information for supporting illness development prediction regarding a neoplasm in a human or animal body. The method includes receiving for the neoplasm first and second image data at a first and second moment in time, and deriving for a plurality of image features a first and a second image feature parameter value from the first and second image data. These feature parameter values being a quantitative representation of a respective image feature. Further, calculating an image feature difference value by calculating a difference between the first and second image feature parameter value, and based on a prediction model deriving a predictive value associated with the neoplasm for supporting treatment thereof. The prediction model includes a plurality of multiplier values associated with image features.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 4, 2019
    Assignee: Stichting Maastricht Radiation Oncology “Maastro-Clinic”
    Inventors: Philippe Lambin, Sara Joao Botelho de Carvalho, Ralph Theodoor Hubertina Leijenaar
  • Patent number: 10279018
    Abstract: Provided herein are immunogenic compositions (vaccines) and methods for immunizing a subject with the immunogenic compositions for inducing an adaptive immune response directed specifically against senescent cells for treatment and prophylaxis of age-related diseases and disorders, and other diseases and disorders associated with or exacerbated by the presence of senescent cells. The immunogenic compositions provided herein comprise at least one or more senescent cell-associated antigens, polynucleotides encoding senescent cell-associated antigens, and recombinant expression vectors comprising the polynucleotides for use in administering to a subject in need thereof.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: May 7, 2019
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH ON AGING, KYTHERA BIOPHARMACEUTICALS, INC.
    Inventors: Alain Philippe Vasserot, Serge Lichtsteiner, Judith Campisi
  • Patent number: 10274501
    Abstract: Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.
    Type: Grant
    Filed: April 30, 2016
    Date of Patent: April 30, 2019
    Assignee: ANP Technologies, Inc.
    Inventors: Ray Yin, Jing Pan, Yli Remo Vallejo, Thomas Small, Dujie Qin, De Chen
  • Patent number: 10261099
    Abstract: Chemokine receptor CCR4 and its ligands CCL17 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL17 and CCL22 provide anti-cancer agents.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: April 16, 2019
    Assignee: Cancer Research Technology Ltd.
    Inventors: Frances Balkwill, Violet Slettenaar, Julia Wilson, Yaohe Wang, Tiziana Schioppa
  • Patent number: 10255410
    Abstract: Disclosed herein are methods for treating Barrett's metaplasia and esophageal adenocarcinoma and methods for determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: April 9, 2019
    Assignee: INTERPACE DIAGNOSTICS CORPORATION
    Inventors: Eric Matthew Gayle Ellsworth, Sydney David Finkelstein, Sara Ann Jackson, Brendan Corcoran, Dennis Morgan Smith, Jr.
  • Patent number: 10234447
    Abstract: The present invention relates to a method for the diagnosis of tumoural conditions and/or of the corresponding state of advance, wherein a specimen of an organic fluid taken from the patient and having a high probability of containing at least one circulating tumor cell (CTC) or a disseminated tumor cell (CTD) is enriched in a population of CTCs or CTDs. According to the invention, at least one type of CTCs or CTDs is isolated by selecting individually single cells in a microfluidic device so to constitute a diagnostic specimen having a purity of at least 90%. On the specimen thus obtained there is subsequently performed a molecular analysis such as to highlight a characteristic thereof suited to enabling diagnosis.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: March 19, 2019
    Assignee: Menarini Silicon Biosystems S.p.A.
    Inventors: Nicolò Manaresi, Gianni Medoro, Giuseppe Giorgini
  • Patent number: 10233484
    Abstract: Disclosed herein are methods and systems for detection of a microorganism of interest using an amplification assay. The methods and systems utilize the specificity of binding agents, such as antibodies, to rapidly detect low levels of a specific microorganism present in a sample. In certain embodiments, antibodies are bound to a large number of the available binding sites on a microorganism.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: March 19, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Dwight Lyman Anderson, Ben Barrett Hopkins, Jose S. Gil, Stephen Erickson, Ekaterina Kovacheva
  • Patent number: 10227656
    Abstract: Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRD1. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRD1 is overexpressed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 12, 2019
    Assignee: Baylor College of Medicine
    Inventors: Bin He, Rainer B. Lanz, Nicholas Mitsiades, Qin Feng
  • Patent number: 10201598
    Abstract: Compositions comprising a nucleic acid molecule that encodes TB esat-6 proteins are disclosed. Methods of inducing an immune response against TB an individual are disclosed. Method of treating an individual who has been diagnosed with TB are disclosed. Method of preventing TB infection in an individual are disclosed.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: February 12, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Daniel Villarreal
  • Patent number: 10188691
    Abstract: The present disclosure provides methods to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds can be used to sensitize resistant cancer cells or decrease the proliferation of cells. The compounds can target proteins in the DNA damage repair pathway leading to a decrease in DNA damage repair in target cells.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 29, 2019
    Assignee: SyntheX, Inc.
    Inventors: Charly Chahwan, Maria Soloveychik
  • Patent number: 10175241
    Abstract: The present invention relates to the assessment of lung cancer. It discloses the use of protein ASC in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: January 8, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Marie-Luise Hagmann, Johann Karl, Markus Roessler, Michael Tacke
  • Patent number: 10168332
    Abstract: The present invention relates to a method for predicting the prognosis of acute myeloid leukemia relapse. According to the present invention, the prognosis of acute myeloid leukemia relapse can be predicted by analyzing changes in a bone marrow microenvironment during the early diagnosis of leukemia.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: January 1, 2019
    Assignee: The Catholic University of Korea Industry-Academic Cooperation Foundation
    Inventor: Il Hoan Oh
  • Patent number: 10145850
    Abstract: This invention relates to a method of detecting or determining the presence of prostate cancer cells in a sample of body fluid from a subject comprising: (i) isolating cells from said sample to provide a cell sample; (ii) contacting said cell sample with a specific binding member capable of binding a prostate antigen; and/or (iii) contacting said cell sample with a specific binding member capable of binding a minichromosome maintenance (MCM) polypeptide(s); and (iv) determining the binding of said specific binding member(s) to the cell sample.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: December 4, 2018
    Inventor: David Brian Galloway
  • Patent number: 10111954
    Abstract: The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-?), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3× anti-CD19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: October 30, 2018
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi, Hans J. Hansen
  • Patent number: 10107814
    Abstract: The invention provides a method of detecting a subject suffering from, or at risk of suffering from, bladder cancer the method comprising i) providing a body fluid sample isolated from a subject; ii) isolating cells from said sample to provide a cell sample; iii) contacting the sample with a specific binding member capable of binding to a minichromosome maintenance (MCM) polypeptide(s); iv) determining the binding of said specific binding member to the cell sample; v) counting those cells in said cell sample which bound to said specific binding member to provide a cell count; vi) determining, based on the cell count, whether the subject has, or is at risk of having, bladder cancer.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: October 23, 2018
    Inventors: David Galloway, Nick Coleman
  • Patent number: 10098971
    Abstract: The present disclosure relates to polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and results in a change in fluorescence based upon the particular pH. In some aspects, the disclosure also provides methods of using the polymers for the imaging of cellular or extracellular environment or delivering a drug.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: October 16, 2018
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Jinming Gao, Gang Huang, Tian Zhao, Xinpeng Ma, Yiguang Wang, Yang Li, Baran D. Sumer